| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1211/JPP.61.10.0002 |
| P698 | PubMed publication ID | 19814858 |
| P50 | author | Nicola Volpi | Q39485241 |
| P2860 | cites work | Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial | Q39871697 |
| Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity. | Q42671875 | ||
| Chicken keel cartilage as a source of chondroitin sulfate | Q44089571 | ||
| Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues | Q44131360 | ||
| Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers | Q44163866 | ||
| Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers | Q44474736 | ||
| The DSD-1 carbohydrate epitope depends on sulfation, correlates with chondroitin sulfate D motifs, and is sufficient to promote neurite outgrowth. | Q48375718 | ||
| Absence of detectable infectivity in trachea of BSE-affected cattle | Q49114481 | ||
| The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial | Q24630475 | ||
| EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) | Q24674132 | ||
| The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor | Q28203275 | ||
| Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis | Q28374250 | ||
| EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q33260652 | ||
| Clinical review of chondroitin sulfate in osteoarthritis | Q33357124 | ||
| Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate | Q34271235 | ||
| The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse | Q34313443 | ||
| The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment | Q35793760 | ||
| Isolation of a neural chondroitin sulfate proteoglycan with neurite outgrowth promoting properties | Q36234537 | ||
| Advances in chondroitin sulfate analysis: application in physiological and pathological States of connective tissue and during pharmacological treatment of osteoarthritis. | Q36393625 | ||
| Therapeutic applications of glycosaminoglycans | Q36512850 | ||
| Chondroitin sulfate as a structure-modifying agent | Q36713898 | ||
| Analytical aspects of pharmaceutical grade chondroitin sulfates. | Q36881374 | ||
| Potential effects of chondroitin sulfate on joint swelling: a GAIT report | Q37167150 | ||
| Potential therapeutic application of chondroitin sulfate/dermatan sulfate | Q37347125 | ||
| Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines | Q38292486 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 1271-1280 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Journal of Pharmacy and Pharmacology | Q10532762 |
| P1476 | title | Quality of different chondroitin sulfate preparations in relation to their therapeutic activity | |
| P478 | volume | 61 |
| Q37951364 | Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule |
| Q47992126 | Anti-oxidant and immune-modulatory properties of sulfated alginate derivatives on human chondrocytes and macrophages |
| Q64253125 | Chondroitin Sulfate Safety and Quality |
| Q34655436 | Chondroitin and glucosamine in the management of osteoarthritis: an update |
| Q36059429 | Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. |
| Q36994144 | Chondroitin sulfate, hyaluronic acid and chitin/chitosan production using marine waste sources: characteristics, applications and eco-friendly processes: a review. |
| Q36675924 | Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee |
| Q35634428 | Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits |
| Q38371965 | Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. |
| Q33810481 | ECM inspired coating of embroidered 3D scaffolds enhances calvaria bone regeneration |
| Q93016657 | Effectiveness of Non-Animal Chondroitin Sulfate Supplementation in the Treatment of Moderate Knee Osteoarthritis in a Group of Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study |
| Q92416265 | Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials |
| Q38090912 | Embroidered and surface coated polycaprolactone-co-lactide scaffolds: a potential graft for bone tissue engineering |
| Q64071545 | Expression, Purification and Characterization of Chondroitinase AC II from Marine Bacterium sp. CS01 |
| Q92372433 | Galactosaminoglycans: Medical Applications and Drawbacks |
| Q47279130 | Glycosaminoglycan and Proteoglycan-Based Biomaterials: Current Trends and Future Perspectives. |
| Q92462051 | Glycosaminoglycans from Co-Products of «Scyliorhinus canicula»: Extraction and Purification in Reference to the European Pharmacopoeia Requirement |
| Q44118071 | Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique |
| Q47816389 | Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). |
| Q54406324 | Investigation of chondroitin sulfate D and chondroitin sulfate E as novel chiral selectors in capillary electrophoresis. |
| Q39083233 | Medical application of glycosaminoglycans: a review |
| Q90439510 | Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers |
| Q34112904 | Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes |
| Q53373309 | Production of chondroitin in metabolically engineered E. coli. |
| Q41978020 | Proteoglycans and their heterogeneous glycosaminoglycans at the atomic scale |
| Q39018675 | Purification and sequence characterization of chondroitin sulfate and dermatan sulfate from fishes |
| Q92691743 | Scientific Papers and Patents on Substances with Unproven Effects. Part 2 |
| Q36141312 | Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum(®) |
| Q55004328 | Terahertz time-domain spectroscopy of chondroitin sulfate. |
| Q37820688 | The quality of commercially available nutraceutical supplements and food sources |
Search more.